Literature DB >> 10511128

Excessive salt or cholesterol intake alters the balance among endothelium-derived factors released from renal arteries in spontaneously hypertensive rats.

S Kagota1, A Tamashiro, Y Yamaguchi, K Nakamura, M Kunitomo.   

Abstract

We investigated the vasorelaxation in renal arteries isolated from spontaneously hypertensive rats (SHRs) fed a basal, a high-salt, or a high-cholesterol diet for 8 weeks. In renal arterial rings from the control group, acetylcholine (ACh)-induced endothelium-dependent relaxations were markedly increased by indomethacin (IND) and ONO-3708, a prostaglandin H2/thromboxane A2-receptor antagonist, but not affected by OKY-046, a thromboxane A2 synthetase inhibitor. These increased relaxations were partially inhibited by either NG-nitro-L-arginine methyl ester (L-NAME) or charybdotoxin (CTX), and almost completely abolished by the combination of L-NAME plus CTX. The ACh-induced endothelium-dependent relaxations in the absence of IND were significantly attenuated by the high-salt intake but not affected by the high-cholesterol intake. The degrees of relaxations in the presence of IND were approximately equal among the three diet groups. On the other hand, the relaxations in the presence of IND plus L-NAME were significantly augmented by a high-cholesterol intake and abolished by a high-salt intake, and the relaxations in the presence of IND plus CTX were slightly reduced by a high-cholesterol intake and significantly augmented by a high-salt intake. The production of cyclic guanosine monophosphate (cGMP) in response to ACh was significantly decreased by a high-cholesterol intake and tended to be increased by a high-salt intake. These findings indicate that in the renal artery of SHRs, ACh causes production of a sufficient amount of nitric oxide (NO), together with a relaxing factor resembling endothelium-derived hyperpolarizing factors (EDHFs) and also endothelium-derived contracting factors (EDCFs), probably prostaglandin H2. Our results also suggest that excessive salt intake increases the release of EDCF and NO and decreases that of an EDHF-like factor, whereas excessive cholesterol intake increases release of an EDHF-like factor and decreases that of NO.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10511128     DOI: 10.1097/00005344-199910000-00009

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

Review 1.  Calcium-activated potassium channels and endothelial dysfunction: therapeutic options?

Authors:  Michel Félétou
Journal:  Br J Pharmacol       Date:  2009-01-29       Impact factor: 8.739

2.  Enhanced endothelium derived hyperpolarising factor activity in resistance arteries from normal pressure glaucoma patients: implications for vascular function in the eye.

Authors:  C Cleary; C H Buckley; E Henry; P McLoughlin; C O'Brien; P W F Hadoke
Journal:  Br J Ophthalmol       Date:  2005-02       Impact factor: 4.638

3.  Contribution of cytochrome P450 metabolites to bradykinin-induced vasodilation in endothelial NO synthase deficient mouse hearts.

Authors:  Zhaoping Ding; Axel Gödecke; Jürgen Schrader
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

4.  Hypertension and the absence of EDHF-mediated responses favour endothelium-dependent contractions in renal arteries of the rat.

Authors:  F S Michel; G S Man; R Y K Man; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  2008-06-23       Impact factor: 8.739

Review 5.  Endothelium-dependent contractions in SHR: a tale of prostanoid TP and IP receptors.

Authors:  Michel Félétou; Tony J Verbeuren; Paul M Vanhoutte
Journal:  Br J Pharmacol       Date:  2009-01-19       Impact factor: 8.739

6.  Endothelium-derived hyperpolarizing factor as an in vivo back-up mechanism in the cutaneous microcirculation in old mice.

Authors:  Marie Line Gaubert; Dominique Sigaudo-Roussel; Maylis Tartas; Gilles Berrut; Jean Louis Saumet; Bérengère Fromy
Journal:  J Physiol       Date:  2007-10-11       Impact factor: 5.182

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.